TREATMENT OF RELAPSED T CELL LYMPHOMAS WITH RECOMBINANT A INTERFERON ALPHA

用重组干扰素α治疗复发性T细胞淋巴瘤

• 批准号: 3963350
• 负责人: R G STEIS
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3963350
• 关键词: dosage; drug adverse effect; human subject; human therapy evaluation; human tissue; interferons; lymphoma; mycosis fungoides lymphoma; neoplasm /cancer immunotherapy; neoplasm /cancer relapse /recurrence

Previous trials have demonstrated activity of recombinant alpha interferon in patients with cutaneous T cell lymphomas. The initial trials used interferon at its maximal tolerated dose, that is, 50 million units per m2 given three times per week. Most patients on this study required dose reduction because of excessive toxicity; and although partial responses were seen in approximately 50 percent of patients, they were of limited duration, and no complete responses were seen. This trial is an attempt to increase the complete response rate and the response duration by administering high doses of interferon daily for five consecutive days followed by a two-week rest period. Also in this study, it was hoped to increase the dose in those patients who were not responding or who had only a partial response.

以前的试验已经证明了重组α干扰素的活性 在皮肤T细胞淋巴瘤患者中。 最初的试验使用 干扰素的最大耐受剂量为5000万单位/m2 每周给药三次。 本研究中的大多数患者需要剂量 减少，因为过度的毒性;虽然部分反应 在大约50%的患者中观察到， 持续时间，未观察到完全缓解。 这次审判是为了 通过以下方式提高完全响应率和响应持续时间： 连续5天每天给予高剂量干扰素 然后是两周的休息期。 在这项研究中，还希望 增加那些没有反应或只有反应的患者的剂量 部分回应。